EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach

Sirajul Islam, Md Al Amin, Kannan R R Rengasamy, A K M Mohiuddin, Shahin Mahmud iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Sirajul Islam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail, 1902, Bangladesh. Hauptthemen laut MEDLINE: Estrogen Receptor beta, Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer, a leading cause of female mortality, is closely linked to mutations in estrogen receptor beta (ESR2), particularly in the ligand‐binding domain, which contributed to altered signaling pathways and uncontrolled cell growth. Objectives/Aims This study investigates the molecular and structural aspects of ESR2 mutant proteins to identify shared pharmacophoric regions of ESR2 mutant proteins and potential therapeutic targets aligned within the pharmacophore model.

Methods

This study was initiated by establishing a common pharmacophore model among three mutant ESR2 proteins (PDB ID: 2FSZ, 7XVZ, and 7XWR). The generated shared feature pharmacophore (SFP) includes four primary binding interactions: Hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), hydrophobic interactions (HPho), and Aromatic interactions (Ar), along with halogen bond donors (XBD) and totalling 11 features (HBD: 2, HBA: 3, HPho: 3, Ar: 2, XBD: 1). By employing an in‐house Python script, these 11 features distributed into 336 combinations, which were used as query to isolate a drug library of 41,248 compounds and subjected to virtual screening through the generated SFP.

Results

The virtual screening demonstrated 33 hits showing potential pharmacophoric fit scores and low RMSD value. The top four compounds: ZINC94272748, ZINC79046938, ZINC05925939, and ZINC59928516 showed a fit score of more than 86% and satisfied the Lipinski rule of five. These four compounds and a control underwent molecular (XP Glide mode) docking analysis against wild‐type ESR2 protein (PDB ID: 1QKM), resulting in binding affinity of −8.26, −5.73, −10.80, and −8.42 kcal/mol, respectively, along with the control −7.2 kcal/mol. Furthermore, the stability of the selected candidates was determined through molecular dynamics (MD) simulations of 200 ns and MM‐GBSA analysis.

Conclusion

Based on MD simulations and MM‐GBSA analysis, our study identified ZINC05925939 as a promising ESR2 inhibitor among the top four hits. However, it is essential to conduct further wet lab evaluation to assess its efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor betaBreast NeoplasmsHumansFemaleMutationMolecular Docking SimulationHydrogen BondingModels, MolecularProtein BindingAntineoplastic AgentsMolecular Dynamics SimulationLigandsPharmacophore

Stichwörter der Autor:innen

MD simulationsZINCPharmerbreast cancerestrogen receptor betamutant ESR2structure based drug designstructure based pharmacophore modeling

Substanzen

Estrogen Receptor betaESR2 protein, humanAntineoplastic AgentsLigands

Autor:innen und Institutionen

  • Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail, 1902, Bangladesh.
  • Laboratory of Natural Products and Medicinal Chemistry (LNPMC), Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai…

ORCID-Profile: Shahin Mahmud

Zitieren

APA

Islam, S., Amin, M. A., Rengasamy, K. R. R., Mohiuddin, A. K. M., & Mahmud, S. (2024). Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach. Cancer Medicine. https://doi.org/10.1002/cam4.70074

Vancouver

Islam S, Amin MA, Rengasamy KRR, Mohiuddin AKM, Mahmud S. Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach. Cancer Medicine. 2024. doi:10.1002/cam4.70074

BibTeX
@article{Islam2024,
  author = {Islam, Sirajul and Amin, Md Al and Rengasamy, Kannan R R and Mohiuddin, A K M and Mahmud, Shahin},
  title = {Structure‐based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70074}
}
Kostenlos starten →